These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 3299817)

  • 1. Does serotonin receptor blockade have a therapeutic effect in Raynaud's phenomenon?
    Brouwer RM; Wenting GJ; Visser W; Schalekamp MA
    Vasa Suppl; 1987; 18():64-7. PubMed ID: 3299817
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
    Arneklo-Nobin B; Elmér O; Akesson A
    Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon.
    Dormandy JA; Berent A; Downes SJ
    Eur J Vasc Surg; 1988 Dec; 2(6):371-5. PubMed ID: 3075559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study.
    van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
    Int Angiol; 1987; 6(3):313-22. PubMed ID: 3329207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.
    Stranden E; Roald OK; Krohg K
    Br Med J (Clin Res Ed); 1982 Oct; 285(6348):1069-71. PubMed ID: 6812750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of alpha-adrenergic blockade in the cardiovascular actions of ketanserin: studies in patients with essential hypertension, autonomic insufficiency, and Raynaud's phenomenon.
    Brouwer RM; Wenting GJ; Man in't Veld AJ; Schalekamp MA
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S26-31. PubMed ID: 2446064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon.
    Arosio E; Montesi G; Zannoni M; Paluani F; Lechi A
    Angiology; 1989 Jul; 40(7):633-8. PubMed ID: 2662829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial.
    van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
    Microcirc Endothelium Lymphatics; 1985; 2(6):657-85. PubMed ID: 2942753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total and capillary fingertip blood flow in Raynaud's phenomenon.
    Coffman JD; Cohen AS
    N Engl J Med; 1971 Jul; 285(5):259-63. PubMed ID: 5090397
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute effects and mechanism of action of ketanserin in patients with primary Raynaud's phenomenon.
    Brouwer RM; Wenting GJ; Schalekamp MA
    J Cardiovasc Pharmacol; 1990 Jun; 15(6):868-76. PubMed ID: 1694908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled comparison of ketanserin and nifedipine in Raynaud's phenomenon.
    Codella O; Caramaschi P; Olivieri O; Perbellini L; Perbellini A; Bambara LM; Corrocher R; De Sandre G
    Angiology; 1989 Feb; 40(2):114-21. PubMed ID: 2644876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketanserin versus nifedipine in secondary Raynaud's phenomenon.
    Kirch W; Linder HR; Hutt HJ; Ohnhaus EE; Mahler F
    Vasa; 1987; 16(1):77-80. PubMed ID: 3554811
    [No Abstract]   [Full Text] [Related]  

  • 14. Ketanserin and capillary flow in Raynaud's phenomenon.
    Tooke JE; Williams SA; Rawlinson DW; Black C
    Int J Microcirc Clin Exp; 1990 Aug; 9(3):249-55. PubMed ID: 2394546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International study of ketanserin in Raynaud's phenomenon.
    Coffman JD; Clement DL; Creager MA; Dormandy JA; Janssens MM; McKendry RJ; Murray GD; Nielsen SL
    Am J Med; 1989 Sep; 87(3):264-8. PubMed ID: 2672807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of Raynaud's syndrome with calcium entry blockers].
    Shcherbakov AB; Guseva NG; Mach ES
    Ter Arkh; 1987; 59(4):89-92. PubMed ID: 3296288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digital pressure and flow measurement upon local cooling in Raynaud's disease. Effect of naftidrofuryl.
    Bounameaux HM; Hellemans H; Verhaege R
    Int Angiol; 1986; 5(1):39-44. PubMed ID: 3734514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laser-Doppler measurement of digital blood flow regulation in normals and in patients with Raynaud's phenomenon.
    Kristensen JK; Engelhart M; Nielsen T
    Acta Derm Venereol; 1983; 63(1):43-7. PubMed ID: 6191488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.
    Seibold JR; Jageneau AH
    Arthritis Rheum; 1984 Feb; 27(2):139-46. PubMed ID: 6365102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laser Doppler flowmeter and standardized thermal test in normals and Raynaud's phenomenon.
    Boccalon HJ; Marguery MC; Ginestet MC; Puel PF
    Int Angiol; 1987; 6(2):107-18. PubMed ID: 3323348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.